Skip to content
Screener

Halozyme Therapeutics HALO Finite Lived Intangible Assets - Gross

Finite Lived Intangible Assets - Gross at other companies

AptarGroup logo
AptarGroupATR
$586.4M+8.8%
Viatris logo
ViatrisVTRS
$33.82B-3.1%
Amgen logo
AmgenAMGN
$54.31B-0.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——

Other financials

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Cash & equivalents$164.0M+165%
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation

See full
Market cap$9.91B+36.0%
Enterprise value$11.93B+36.1%
P/E13.8×-3.9×
P/S6×-0.2×

Profitability

See full
Gross margin82.4%-1.8pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001159036-26-000104
Line itemWeighted Average Useful Life (in years)Gross Carrying ValueAccumulated AmortizationNet Carrying Value
Auto-injector technology platform7$402,000$235,735$166,265
XYOSTED proprietary product10136,20055,90880,292
Hypercon developed technology platform15230,0009,498220,502
Customer relationships (1)15470,00019,410450,590
Trade name155,0002064,794
Total intangible assets, net$1,243,200$320,757$922,443

Item 1. Financial Statements

FAQ

What is Halozyme Therapeutics's finite lived intangible assets - gross?
Halozyme Therapeutics (HALO) reported finite lived intangible assets - gross of $1.24B in Q2 2026.
How has Halozyme Therapeutics's finite lived intangible assets - gross changed year-over-year?
Halozyme Therapeutics's finite lived intangible assets - gross increased by 131.0% year-over-year, from $538.2M to $1.24B.
What does finite lived intangible assets - gross mean?
This metric tracks the total historical cost of intangible assets that have a defined useful life, such as patents, software licenses, or customer relationships. It excludes assets with indefinite lives like certain trademarks or goodwill. It is a key indicator of the company's investment in intellectual property and intangible competitive advantages.

Ask your AI about Halozyme Therapeutics's finite lived intangible assets - gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude